SCHEMBL25720776

SCHEMBL25720776

COC(=O)c1cccc(OCc2ccccc2)c1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.63
L3MBTL1 Q9Y468 3/20 0.63
TDP1 Q9NUW8 2/20 0.63
MAPK1 P28482 1/20 0.63
RAB9A P51151 2/20 0.60
LMNA P02545 2/20 0.60
PTGER1 P34995 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
SGMS2 Q8NHU3 2/20 0.54
BRD4 O60885 1/20 0.51
NPC1 O15118 2/20 0.51
HTT P42858 1/20 0.51
EDNRA P25101 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HPGD P15428 2/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16319063 0.88 L3MBTL1 (0.63) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL978857 0.88 HTT (0.64) MAPTL3MBTL1LMNAPTGER1SMN1; SMN2
SCHEMBL410077 0.86 PTGER1 (0.76) MAPTL3MBTL1TDP1MAPK1PTGER1
SCHEMBL29930977 0.85 SGMS2 (0.54) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL1305662 0.85 HPGD (0.57) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL5940976 0.85 SGMS2 (0.54) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL1097551 0.85 SGMS2 (0.54) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL23611725 0.84 NPC1 (0.60) RAB9ALMNAPTGER1SMN1; SMN2SGMS2
SCHEMBL34466882 0.84 L3MBTL1 (0.53) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL29930885 0.84 NPC1 (0.60) RAB9ALMNAPTGER1SMN1; SMN2SGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192629-A1 METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES AMO PHARMA LTD. (US) 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192629-A1 METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES FNTB, FNTA, FDPS MAPT 2499/4885L3MBTL1 3660/4885TDP1 3369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.